Sugi Predict

Sugi Predict / Compounds / SCHEMBL199794

SCHEMBL199794

SCHEMBL199794

[CH2]CCCCCC(C)CCCC

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACE2 Q9BYF1 1/20 0.47
▸ LMNA P02545 2/20 0.42
▸ DNM1 Q05193 2/20 0.40
▸ OPRM1 P35372 1/20 0.39
▸ PRKD3 O94806 1/20 0.37
▸ PRKCG P05129 1/20 0.37
▸ PRKCB P05771 1/20 0.37
▸ PRKCA P17252 1/20 0.37
▸ PRKCH P24723 1/20 0.37
▸ PRKCI P41743 1/20 0.37
▸ PRKCE Q02156 1/20 0.37
▸ PRKCQ Q04759 1/20 0.37
▸ PRKCZ Q05513 1/20 0.37
▸ PRKCD Q05655 1/20 0.37
▸ PRKD1 Q15139 1/20 0.37
▸ SPHK1 Q9NYA1 1/20 0.37
▸ ADH1B P00325 1/20 0.34
▸ ADH1C P00326 1/20 0.34
▸ ADH1A P07327 1/20 0.34
▸ ADH4 P08319 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27039032 1.00 ACE2 (0.47) ACE2LMNADNM1OPRM1PRKD3
SCHEMBL6764178 1.00 ACE2 (0.47) ACE2LMNADNM1OPRM1PRKD3
SCHEMBL27038952 1.00 ACE2 (0.47) ACE2LMNADNM1OPRM1PRKD3
SCHEMBL27039098 1.00 ACE2 (0.47) ACE2LMNADNM1OPRM1PRKD3
SCHEMBL7104064 1.00 ACE2 (0.47) ACE2LMNADNM1OPRM1PRKD3
SCHEMBL5086553 1.00 ACE2 (0.47) ACE2LMNADNM1OPRM1PRKD3
SCHEMBL25185980 1.00 ACE2 (0.47) ACE2LMNADNM1OPRM1PRKD3
SCHEMBL9745732 1.00 ACE2 (0.47) ACE2LMNADNM1OPRM1PRKD3
SCHEMBL7101548 1.00 ACE2 (0.47) ACE2LMNADNM1OPRM1PRKD3
SCHEMBL9747272 1.00 ACE2 (0.47) ACE2LMNADNM1OPRM1PRKD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024147345-A1 COATED NEGATIVE ELECTRODE ACTIVE MATERIAL PARTICLES FOR LITHIUM ION BATTERIES, NEGATIVE ELECTRODE FOR LITHIUM ION BATTERIES, LITHIUM ION BATTERY, AND METHOD FOR PRODUCING COATED NEGATIVE ELECTRODE ACTIVE MATERIAL PARTICLES FOR LITHIUM ION BATTERIES ＡＰＢ株式会社 2024-07-11 — — WO disclosed
CN-118201905-A Cationic lipid 武田药品工业株式会社 2024-06-14 — — CN disclosed
US-20240024252-A1 LIPID NANOPARTICLE NITTO DENKO CORPORATION (JP) 2024-01-25 — — US disclosed
CN-117062872-A Polymer composition comprising a polyacrylic block copolymer and an aromatic polyoxyalkylene as dispersant 巴斯夫欧洲公司 2023-11-14 — — CN disclosed
WO-2023204215-A1 ELECTRODE COMPOSITION FOR LITHIUM ION BATTERIES, COATED NEGATIVE ELECTRODE ACTIVE MATERIAL PARTICLES FOR LITHIUM ION BATTERIES, METHOD FOR PRODUCING COATED NEGATIVE ELECTRODE ACTIVE MATERIAL PARTICLES FOR LITHIUM ION BATTERIES, NEGATIVE ELECTRODE FOR LITHIUM ION BATTERIES, AND LITHIUM ION BATTERY ＡＰＢ株式会社 2023-10-26 — — WO disclosed
WO-2023191032-A1 ELECTRODE FOR LITHIUM-ION BATTERY, AND LITHIUM-ION BATTERY ＡＰＢ株式会社 2023-10-05 — — WO disclosed
US-20230317953-A1 COATED NEGATIVE ELECTRODE ACTIVE MATERIAL PARTICLES FOR LITHIUM ION BATTERIES, NEGATIVE ELECTRODE FOR LITHIUM ION BATTERIES, LITHIUM ION BATTERY, AND METHOD FOR PRODUCING COATED NEGATIVE ELECTRODE ACTIVE MATERIAL PARTICLES FOR LITHIUM ION BATTERIES APB CORPORATION (JP) 2023-10-05 — — US disclosed
WO-2023157927-A1 POSITIVE ELECTRODE COMPOSITION FOR LITHIUM ION BATTERY ＡＰＢ株式会社 2023-08-24 — — WO disclosed
WO-2023157925-A1 NEGATIVE ELECTRODE COMPOSITION FOR LITHIUM-ION BATTERY ＡＰＢ株式会社 2023-08-24 — — WO disclosed
EP-4223314-A1 LIPID NANOPARTICLE National University Corporation Hokkaido University (JP) 2023-08-09 — — EP disclosed
US-6395701-B1 MIXTURE PROCTER & GAMBLE COMPANY, THE 2002-05-28 — — US disclosed
US-6313164-B1 TO ENHANCE THE ACTIVITY OF GLUTATHIONE RECLUCTASE; FOR THERAPY AND PROPHYLAXIS OF CARTARACTS SANKYO COMPANY, LIMITED (JP) 2001-11-06 — — US disclosed
EP-1070710-A2 Dithiolan derivatives, their preparation and their therapeutic effect Sankyo Company Limited (JP) 2001-01-24 — — EP disclosed
EP-1025190-A2 FATTY ACIDS, SOAPS, SURFACTANT SYSTEMS, AND CONSUMER PRODUCTS BASED THEREON THE PROCTER & GAMBLE COMPANY (US) 2000-08-09 — — EP disclosed
US-6013663-A CATARACT THERAPY OR PREVENTION SANKYO COMPANY, LIMITED (JP) 2000-01-11 — — US disclosed
WO-1999020722-A2 FATTY ACIDS, SOAPS, SURFACTANT SYSTEMS, AND CONSUMER PRODUCTS BASED THEREON THE PROCTER & GAMBLE COMPANY (US) 1999-04-29 — — WO disclosed
CN-1208035-A Dithiolan derivatives, their preparation and their therapeutic effect SANKYO CO (JP) 1999-02-17 — — CN disclosed
EP-0888334-A1 2-HETAROYLCYCLOHEXANE-1,3-DIONES BASF AKTIENGESELLSCHAFT (DE) 1999-01-07 — — EP disclosed
EP-0869126-A1 Dithiolan derivatives, their preparation and their therapeutic effect Sankyo Company Limited (JP) 1998-10-07 — — EP disclosed
WO-1997030986-A1 2-HETAROYLCYCLOHEXANE-1,3-DIONES BASF AKTIENGESELLSCHAFT (DE) 1997-08-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240024252-A1 LIPID NANOPARTICLE LIPC, ACOX1, ABCB4 ACE2 2922/4885LMNA 1094/4885DNM1 2497/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.